SCHEMBL18200723

SCHEMBL18200723

c1ccc2c(-c3nc(-c4ccc(-c5nc6ccccc6c6c5ccc5ccccc56)cn4)nc(-c4cccc5ccccc45)n3)cccc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NPC1 O15118 2/20 0.35
LMNA P02545 1/20 0.35
RECQL P46063 1/20 0.35
RAB9A P51151 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 4/20 0.34
ALDH1A1 P00352 4/20 0.34
HPGD P15428 4/20 0.34
ATM Q13315 2/20 0.34
TP53 P04637 2/20 0.34
MAPK1 P28482 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18200378 0.92 MEN1 (0.36) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18201042 0.91 MEN1 (0.39) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18200544 0.90 MEN1 (0.44) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18201264 0.89 MEN1 (0.36) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18200716 0.88 METAP1 (0.45) MAPTNPC1LMNARECQLRAB9A
SCHEMBL18200708 0.87 AURKA (0.36) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18200477 0.87 MEN1 (0.38) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18200547 0.87 MAPT (0.41) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18201308 0.86 MAPT (0.40) MAPTSMN1; SMN2NPC1LMNARECQL
SCHEMBL18200864 0.86 MEN1 (0.39) MAPTSMN1; SMN2NPC1LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME HEESUNG MATERIAL LTD. (KR) 2016-12-29 US disclosed
EP-3088392-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME Heesung Material Ltd. (KR) 2016-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME NOTUM, DDT, CRY1 MAPT 1937/4885SMN1; SMN2 3944/4885NPC1 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.